TSHA
Taysha Gene Therapies Inc
Price:  
1.70 
USD
Volume:  
1,193,726.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

TSHA WACC - Weighted Average Cost of Capital

The WACC of Taysha Gene Therapies Inc (TSHA) is 7.2%.

The Cost of Equity of Taysha Gene Therapies Inc (TSHA) is 7.50%.
The Cost of Debt of Taysha Gene Therapies Inc (TSHA) is 7.00%.

Range Selected
Cost of equity 6.60% - 8.40% 7.50%
Tax rate 26.20% - 27.00% 26.60%
Cost of debt 7.00% - 7.00% 7.00%
WACC 6.5% - 8.0% 7.2%
WACC

TSHA WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 0.6 0.63
Additional risk adjustments 0.0% 0.5%
Cost of equity 6.60% 8.40%
Tax rate 26.20% 27.00%
Debt/Equity ratio 0.13 0.13
Cost of debt 7.00% 7.00%
After-tax WACC 6.5% 8.0%
Selected WACC 7.2%